Nabriva Therapeutics PLC – (NASDAQ:NBRV) shares shot up 7.3% on Monday . The stock traded as high as $1.91 and last traded at $1.91, 794,600 shares traded hands during trading. A decline of 31% from the average session volume of 1,145,218 shares. The stock had previously closed at $1.78.
Several research firms recently weighed in on NBRV. Northland Securities set a $13.00 price objective on shares of Nabriva Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 16th. BidaskClub cut shares of Nabriva Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, October 1st. Wedbush reaffirmed an “outperform” rating and set a $5.00 price objective on shares of Nabriva Therapeutics in a research report on Friday, August 9th. Bank of America set a $6.00 price objective on shares of Nabriva Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, August 20th. Finally, HC Wainwright set a $7.00 price objective on shares of Nabriva Therapeutics and gave the stock a “buy” rating in a research report on Sunday, August 18th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $7.06.
The company’s 50-day moving average is $2.06 and its two-hundred day moving average is $2.32. The company has a debt-to-equity ratio of 0.56, a current ratio of 5.67 and a quick ratio of 5.67. The firm has a market cap of $1.40 billion, a P/E ratio of -1.17 and a beta of 2.43.
In related news, CEO Theodore R. Schroeder bought 50,000 shares of the company’s stock in a transaction dated Tuesday, August 27th. The stock was purchased at an average price of $1.79 per share, with a total value of $89,500.00. Following the completion of the acquisition, the chief executive officer now owns 5,786 shares of the company’s stock, valued at $10,356.94. The purchase was disclosed in a document filed with the SEC, which is available through this link. In the last three months, insiders bought 64,977 shares of company stock valued at $119,951 and sold 21,773 shares valued at $45,186. 3.32% of the stock is currently owned by corporate insiders.
Several hedge funds have recently bought and sold shares of NBRV. FMR LLC grew its position in Nabriva Therapeutics by 77.0% in the 1st quarter. FMR LLC now owns 3,261,500 shares of the biotechnology company’s stock worth $7,958,000 after purchasing an additional 1,418,800 shares during the last quarter. Commonwealth Equity Services LLC grew its position in Nabriva Therapeutics by 30.0% in the 2nd quarter. Commonwealth Equity Services LLC now owns 65,010 shares of the biotechnology company’s stock worth $157,000 after purchasing an additional 15,000 shares during the last quarter. Wells Fargo & Company MN acquired a new stake in Nabriva Therapeutics in the 2nd quarter worth $169,000. JPMorgan Chase & Co. grew its position in Nabriva Therapeutics by 92.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 323,857 shares of the biotechnology company’s stock worth $719,000 after purchasing an additional 155,815 shares during the last quarter. Finally, Renaissance Technologies LLC grew its position in Nabriva Therapeutics by 51.8% in the 2nd quarter. Renaissance Technologies LLC now owns 1,299,365 shares of the biotechnology company’s stock worth $3,157,000 after purchasing an additional 443,600 shares during the last quarter. 3.89% of the stock is owned by hedge funds and other institutional investors.
Nabriva Therapeutics Company Profile (NASDAQ:NBRV)
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
Read More: Buyback
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.